With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of ...

Bearish flow noted in AbbVie (ABBV) with 6,427 puts trading, or 1.5x expected. Most active are 4/11 weekly 210 puts and Mar-25 190 calls, with ...

Forget the old adage “it takes money to make money.” In the stock market, even a measly $500 can kickstart a fortune. Time, not a fat wallet, is the real MVP here. With the right picks, that modest ...

As previously reported, Erste Group upgraded AbbVie (ABBV) to Buy from Hold. The firm notes AbbVie recently confirmed its expectations for ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

AbbVie Inc. stands out as one of the top pharma stocks to buy, according to hedge funds. The company exceeded analyst ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

REITs pay dividends out of their funds from operations (FFO), and Vici's FFO per share is $2.61 over the last 12 months. This ...